Ensoma Reports First Clinical Safety Data for Groundbreaking In Vivo Hematopoietic Stem Cell Gene Therapy
核心洞察
Ensoma (搜索)'s EN-374 represents the first-ever in vivo hematopoietic stem cell gene insertion therapy to reach clinical trials, marking a significant milestone in gene therapy development.
Initial Phase 1/2 safety data from the first patient with X-linked chronic granulomatous disease (搜索) showed good tolerability with only low-grade adverse events and no serious adverse events or dose-limiting toxicities.
The therapy uses virus-like particles to deliver genetic payloads directly to hematopoietic stem cells in vivo, potentially creating a continuous source of therapeutic immune and blood cells.
Ensoma (搜索) has achieved a significant milestone in gene therapy by reporting the first clinical safety data for EN-374, the world's first in vivo hematopoietic stem cell (HSC (搜索)) gene insertion therapy. The initial Phase 1/2 safety data from the first participant with X-linked chronic granulomatous disease (搜索) (X-CGD (搜索)) demonstrate encouraging tolerability, marking a breakthrough in directly engineering stem cells within the patient's body.
First-in-Human Safety Results Show Promise
The initial clinical data from the first participant in Ensoma (搜索)'s Phase 1/2 trial revealed that the treatment was well tolerated across all components of the therapy protocol. The comprehensive treatment regimen, which included HSC (搜索) mobilization, gene therapy infusion, short-course immune prophylaxis, and three cycles of enrichment, showed a favorable safety profile.
"We are excited to discuss encouraging initial safety data from the first participant in our Phase 1/2 clinical trial of EN-374 for X-CGD (搜索), the first-ever in vivo HSC (搜索) gene insertion therapy in the clinic," said Jim Burns, CEO of Ensoma (搜索). "While these are early data from a single participant, they mark an important first step in evaluating a new approach to engineering hematopoietic stem cells directly in vivo."
All adverse events observed were classified as low-grade, with no serious adverse events or dose-limiting toxicities reported. The company noted that follow-up to assess potential efficacy is ongoing and will be reported at a later date.
Revolutionary Approach to Genetic Disease Treatment
EN-374 represents a paradigm shift in treating X-CGD (搜索) by employing virus-like particles (VLPs) to deliver payloads containing a CYBB (搜索) transgene directly to hematopoietic stem cells. This approach enables neutrophils arising from the engineered HSCs to express the protein product of the CYBB transgene, potentially restoring function of the infection-fighting NADPH oxidase (搜索) enzyme complex critical for immune defense.
The therapy builds on mechanisms previously validated ex vivo but represents the first attempt to engineer HSCs directly within the patient's body. In preclinical studies, EN-374 demonstrated therapeutic levels of restoration of CYBB (搜索) gene expression and NADPH oxidase (搜索) activity in circulating neutrophils.
Advanced Viral Vector Technology Shows Promise
Ensoma (搜索) also presented data on engineered neutralizing antibody-evading helper-dependent adenovirus capsids designed to overcome a significant barrier in gene delivery. The company developed a series of hexon-modified helper-dependent adenovirus (HDAd) capsids specifically designed to evade pre-existing Ad5 neutralizing antibodies, which represent a known obstacle to effective gene delivery.
The research identified an optimized capsid variant called HDAdGen2 that demonstrated successful evasion of neutralizing antibodies in human sera while maintaining transduction efficiency comparable to the standard HDAd5/35++ vector both in vitro and in vivo. These findings suggest potential to improve gene delivery in patients with pre-existing immunity to Ad5.
Breakthrough Cancer Immunotherapy Platform
In addition to the genetic disease applications, Ensoma (搜索) presented preclinical data demonstrating the potential of their platform for cancer (搜索) treatment. The company developed lineage-restricted regulatory elements to drive CAR expression selectively in myeloid, NK, and T cell populations, creating a multiplexed approach to cancer immunotherapy.
The preclinical studies in HER2+ tumor (搜索) models showed durable tumor control and prolonged survival in treated animals compared to controls. Importantly, the treatment maintained normal hematopoiesis and immune cell differentiation following HSC (搜索) engineering, supporting the potential of a multi-lineage, in vivo-generated cell therapy approach for solid tumors.
Platform Technology with Broad Applications
Ensoma (搜索)'s platform combines proprietary base editing and high-efficiency gene integration systems with high-capacity virus-like particles capable of carrying up to 35 kilobases of genetic material. In preclinical animal studies, these VLPs preferentially bind to hematopoietic stem cells and efficiently deliver DNA to the nucleus.
The platform's versatility allows it to carry sophisticated genomic engineering tools capable of changes ranging from single base edits to large multi-gene insertions, along with control elements for HSC (搜索)-lineage cell specific expression. This broad capability positions the technology to address genetic diseases (搜索), immune disorders (搜索), and cancer (搜索) through in vivo cellular engineering.
Clinical Trial Design and Future Development
The ongoing Phase 1/2 study is an open-label, multicenter clinical trial conducted in the US and UK. The trial is evaluating the safety, tolerability, pharmacodynamics, and efficacy biomarkers of EN-374, with the primary goal of identifying an optimal dose for further clinical development in X-CGD (搜索) patients.
The data presented at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting represent the first reported clinical experience with in vivo HSC (搜索)-directed therapy, potentially offering patients a continuous source of therapeutic immune and blood cells to treat disease.